JKC 301

• Description:

  JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking[1][2].

• UNSPSC:

  12352209

• Target:

  Vasopressin Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/jkc-301.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](C(N(CCC1)[C@]1([H])C2=O)=O)CC(O)=O)[C@H](NC([C@@H](NC([C@@](N2)([H])[C@H](C)CC)=O)CC(C)C)=O)CC3=CNC4=CC=CC=C34

• Molecular Formula:

  C32H44N6O7

• Molecular Weight:

  624.73

• References & Citations:

  [1]Tanus-Santos JE, Sampaio RC, Hyslop S, Franchini KG, Moreno H Jr. Endothelin ET (A) receptor antagonism attenuates the pressor effects of nicotine in rats. Eur J Pharmacol. 2000 May 12;396 (1) :33-7. |[2]Ngoka LC, et al. Location of alkali metal binding sites in endothelin A selective receptor antagonists, cyclo (D-Trp-D-Asp-Pro-D-Val-Leu) and cyclo (D-Trp-D-Asp-Pro-D-Ile-Leu), from multistep collisionally activated decompositions. J Mass Spectrom. 2000 Feb;35 (2) :265-76.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  [136553-96-3]